Matches in Wikidata for { <http://www.wikidata.org/entity/Q91808730> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q91808730 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91808730 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91808730 description "scientific article published on 07 April 2020" @default.
- Q91808730 description "wetenschappelijk artikel" @default.
- Q91808730 description "наукова стаття, опублікована 7 квітня 2020" @default.
- Q91808730 name "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 name "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 type Item @default.
- Q91808730 label "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 label "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 prefLabel "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 prefLabel "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 P1433 Q91808730-76B6975A-75AB-49B5-98E8-C8535A884860 @default.
- Q91808730 P1476 Q91808730-EAFCB628-D8FA-4401-A5AE-25C8169AE127 @default.
- Q91808730 P2093 Q91808730-0EBEDA3B-58FD-4BE5-BA3D-0FB2C758CC88 @default.
- Q91808730 P2093 Q91808730-1A1D9EF6-CD53-4CCB-821C-13C79BA09673 @default.
- Q91808730 P2093 Q91808730-E825E4E6-D5C6-4E09-9385-D1BFF52FD608 @default.
- Q91808730 P2093 Q91808730-FDF638AB-BF93-44E5-B19F-DAF1B2B89F51 @default.
- Q91808730 P304 Q91808730-660B99EF-4396-44B8-B269-7211ACEEAC8E @default.
- Q91808730 P31 Q91808730-46450CE9-A940-4DF5-AEF2-26BAFAFDAE84 @default.
- Q91808730 P356 Q91808730-C19A15DB-1B87-46AB-BEA5-B8F07DCDA1D4 @default.
- Q91808730 P577 Q91808730-3D9F80AA-F1F4-4F71-A171-9276282A8F3C @default.
- Q91808730 P698 Q91808730-0E71AA63-ACD5-4211-A6EC-F7F2B3218E49 @default.
- Q91808730 P921 Q91808730-1FA3D4C8-B74E-42C2-B4C8-1180350975D6 @default.
- Q91808730 P921 Q91808730-C53FF671-4BC2-4546-8351-3EE3A5F357DE @default.
- Q91808730 P356 J.IJPHARM.2020.119307 @default.
- Q91808730 P698 32276090 @default.
- Q91808730 P1433 Q6051539 @default.
- Q91808730 P1476 "The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation" @default.
- Q91808730 P2093 "Arik Dahan" @default.
- Q91808730 P2093 "Avital Beig" @default.
- Q91808730 P2093 "Jonathan M Miller" @default.
- Q91808730 P2093 "Noa Fine-Shamir" @default.
- Q91808730 P304 "119307" @default.
- Q91808730 P31 Q13442814 @default.
- Q91808730 P356 "10.1016/J.IJPHARM.2020.119307" @default.
- Q91808730 P577 "2020-04-07T00:00:00Z" @default.
- Q91808730 P698 "32276090" @default.
- Q91808730 P921 Q410412 @default.
- Q91808730 P921 Q461809 @default.